Abstract
The present invention relates to methods that use novel biomarkers for predicting the response to glucagon-like peptide-1 (GLP-1) analogue therapy in a diabetic patient. The novel biomarkers of the invention show altered cytosine methylations state of certain CpG loci and the presence of a specific single nucleotide polymorphism (SNP) in diabetic patient less responsive to Glucagon-like peptide-1 (GLP-1) analogue to relative to diabetic subject responsive GLP-1 analogue.
| Translated title of the contribution | METHOD FOR PREDICTING THE RESPONSE TO GLUCAGON-LIKE PEPTIDE-1 ANALOGUE THERAPY |
|---|---|
| Original language | Chinese (Traditional) |
| Patent number | I755027 |
| IPC | G01N 33/68(2006.01); G01N 33/74(2006.01) |
| State | Published - 11 02 2022 |
Bibliographical note
公開公告號: I755027Announcement ID: I755027
